Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Subpoena For Sun Amid Pricing Heat

Executive Summary

US lawmakers continue to scrutinize drug firms amid ongoing concerns over price-related issues and their impact on healthcare costs. The US Justice Department’s antitrust division has subpoenaed Sun Pharma for information pertaining to generic drugs, pricing and certain company records, though the Indian firm claimed the move would have no immediate impact on its earnings.

You may also be interested in...

Skyrocketing US generic prices: blame it on compliance costs, ''inspection raj''

Ok, now for the Indian industry's take on why generic prices may have surged in the US, against the backdrop of the probe by Senator Bernie Sanders and Representative Elijah Cummings. Put simply, much of the Indian defense can be read as: You brought this upon yourself.

US Capitol Capsule: Biopharma patent law back at Supreme Court with Copaxone

The US Supreme Court is starting off its 2014-15 session with yet another patent case involving biopharmaceutical companies – this time Teva and its money-maker multiple sclerosis drug Copaxone (glatiramer acetate), whose last remaining patent was declared invalid by the US Court of Appeals for the Federal Circuit in July 2013.

The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts